NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.
NAMS has been the subject of a number of other reports. BMO Capital Markets started coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $52.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, October 15th. Jefferies Financial Group restated a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Finally, Royal Bank Of Canada reduced their target price on NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.90.
Get Our Latest Stock Report on NAMS
NewAmsterdam Pharma Trading Down 8.7%
Shares of NAMS stock opened at $19.71 on Friday. NewAmsterdam Pharma has a 12-month low of $19.13 and a 12-month high of $42.21. The company has a market capitalization of $2.36 billion, a P/E ratio of -9.12 and a beta of 0.10. The business’s 50 day moving average is $23.54 and its two-hundred day moving average is $29.21.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. On average, research analysts predict that NewAmsterdam Pharma will post -1.82 earnings per share for the current fiscal year.
Insider Activity at NewAmsterdam Pharma
In related news, CEO Michael Davidson acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average cost of $22.65 per share, for a total transaction of $226,500.00. Following the completion of the acquisition, the chief executive officer directly owned 792,923 shares of the company’s stock, valued at approximately $17,959,705.95. This trade represents a 1.28% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Johannes Kastelein sold 50,246 shares of the company’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $25.03, for a total transaction of $1,257,657.38. Following the transaction, the insider owned 69,302 shares in the company, valued at approximately $1,734,629.06. The trade was a 42.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 176,846 shares of company stock valued at $4,661,919 in the last 90 days. 12.74% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. boosted its stake in shares of NewAmsterdam Pharma by 6.8% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock worth $613,033,000 after purchasing an additional 1,145,128 shares during the period. Maverick Capital Ltd. boosted its holdings in NewAmsterdam Pharma by 15.4% in the first quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock worth $69,987,000 after acquiring an additional 292,176 shares in the last quarter. Bank of America Corp DE increased its position in shares of NewAmsterdam Pharma by 84.4% in the 1st quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock valued at $27,115,000 after acquiring an additional 387,698 shares during the period. SEB Asset Management AB purchased a new stake in NewAmsterdam Pharma in the first quarter valued at $8,728,000. Finally, Stempoint Capital LP grew its position in shares of NewAmsterdam Pharma by 147.1% during the 1st quarter. Stempoint Capital LP now owns 180,658 shares of the company’s stock valued at $5,783,000 after acquiring an additional 107,552 shares during the period. 89.89% of the stock is owned by hedge funds and other institutional investors.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.
NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.
Featured Articles
- Five stocks we like better than NewAmsterdam Pharma
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
